AECOM awarded three U.S. Army Corps of Engineers contracts to support critical infrastructure modernization across the Pacific Region
'AECOM has proudly partnered with the Honolulu District for more than six decades, and these new awards represent a continued commitment to advancing the U.S. Department of Defense's Pacific Deterrence Initiative throughout the region," said Matt Crane, chief executive of AECOM's U.S. West region. "From environmental planning to civil and architectural design, we bring deep local knowledge and leading-edge technical solutions to deliver resilient, sustainable outcomes."
AECOM will support USACE in advancing critical infrastructure projects aimed at increasing capacity, modernizing existing facilities, and supporting long-term mission readiness across the Pacific area of responsibility. AECOM's scope includes providing environmental planning services, delivering sustainable architectural and civil design solutions, and providing strategic planning expertise tailored to the unique challenges of the Pacific region.
"This is an exciting award for our teams, particularly as confirmation of our strong architectural and design role in the region," said Bane Gaiser, chief executive of AECOM's global Buildings + Places business. "It's a reflection of our long-standing local partnerships, digital innovations, and strong track record delivering infrastructure that meets today's needs while preparing for tomorrow's challenges."
AECOM has extensive expertise in the region, demonstrated through a strong track record of successful project delivery. Significant projects include the award-winning U.S. Army Pacific Command and Control Facility at Fort Shafter, the Echo Pier restoration on the Kwajalein Atoll, the Sand Island Wastewater Secondary Treatment Plant upgrade in Honolulu, the Pearl Harbor Naval Shipyard Dry Dock Environmental Impact Statement, and the Pearl Harbor Naval Shipyard and Intermediate Maintenance Facility Area Development Plan.
About AECOM
AECOM (NYSE: ACM) is the global infrastructure leader, committed to delivering a better world. As a trusted professional services firm powered by deep technical abilities, we solve our clients' complex challenges in water, environment, energy, transportation and buildings. Our teams partner with public- and private-sector clients to create innovative, sustainable and resilient solutions throughout the project lifecycle – from advisory, planning, design and engineering to program and construction management. AECOM is a Fortune 500 firm that had revenue of $16.1 billion in fiscal year 2024. Learn more at aecom.com.
Forward Looking Statements
All statements in this communication other than statements of historical fact are 'forward-looking statements' for purposes of federal and state securities laws, including any statements of the plans, strategies and objectives for future operations, profitability, strategic value creation, capital allocation strategy including stock repurchases, risk profile and investment strategies, and any statements regarding future economic conditions or performance, and the expected financial and operational results of AECOM. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in our forward-looking statements include, but are not limited to, the following: our business is cyclical and vulnerable to economic downturns and client spending reductions; potential government shutdowns, changes in administration or other funding directives and circumstances that may cause governmental agencies to modify, curtail or terminate our contracts; losses under fixed-price contracts; limited control over operations that run through our joint venture entities; liability for misconduct by our employees or consultants; changes in government laws, regulations and policies, including failure to comply with laws or regulations applicable to our business; maintaining adequate surety and financial capacity; potential high leverage and inability to service our debt and guarantees; ability to continue payment of dividends; exposure to political and economic risks in different countries, including tariffs and trade policies, geopolitical events, and conflicts; inflation, currency exchange rates and interest rate fluctuations; changes in capital markets and stock market volatility; retaining and recruiting key technical and management personnel; legal claims and litigation; inadequate insurance coverage; environmental law compliance and adequate nuclear indemnification; unexpected adjustments and cancellations related to our backlog; partners and third parties who may fail to satisfy their legal obligations; managing pension costs; AECOM Capital real estate development projects; cybersecurity issues, IT outages and data privacy; risks associated with the benefits and costs of the sale of our Management Services and self-perform at-risk civil infrastructure, power construction and oil and gas businesses, including the risk that any purchase adjustments from those transactions could be unfavorable and result in any future proceeds owed to us as part of the transactions could be lower than we expect; as well as other additional risks and factors that could cause actual results to differ materially from our forward-looking statements set forth in our reports filed with the Securities and Exchange Commission. Any forward-looking statements are made as of the date hereof. We do not intend, and undertake no obligation, to update any forward-looking statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Why Lemonade Stock Dropped 14% in July, and Why It's Already Rebounding
Key Points Lemonade stock was sagging last month as home sales are still disappointing, and home insurance is its core product. Despite that, Lemonade reported outstanding second-quarter results. Lemonade stock could still be a bargain. 10 stocks we like better than Lemonade › Shares of insurance technology company Lemonade (NYSE: LMND) dropped 14% in July, according to data provided by S&P Global Market Intelligence. There wasn't any significant news directly related to the company, but the descent started after home sales data were released on July 23, and home insurance is a big part of Lemonade's business today. However, it dispelled those worries with a fantastic second-quarter report. The housing market is still sour Lemonade is a digital insurance company that sells insurance online, mostly through chatbots. It uses artificial intelligence (AI) and machine learning throughout its business, and its algorithms determine everything from policy pricing to regional marketing spend. It's only a decade old, but it's already made a strong mark on the industry, expanding its platform to cover most kinds of insurance and reaching most of the U.S. population. It's growing rapidly as customers enjoy the concept of being able to file a claim online and have it approved within minutes instead of needing to wait on hold for an insurance agent to answer their calls. Lemonade's original product was renters insurance, and renters and homeowners insurance are still the company's main products, accounting for about half of total in-force premium (IFP). Home sales data released in July from the National Association of Realtors showed that home sales hit a record high of $435,300 in June, up 2% from the year before, and pending home sales fell 0.8% from May. Experts were expecting 0.2%. People are holding off on buying homes, and the market was concerned about Lemonade's growth prospects. Sweetening the deal Lemonade released second-quarter earnings on Tuesday morning, and they were phenomenal, beating expectations across the board. IFP increased 29% year over year to over $1 billion, and total customer count increased 24% to nearly 2.7 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss and net loss both contracted year over year, and the trailing-12-month loss ratio improved by 3 percentage points sequentially. Home-related loss ratio, a metric associated with its oldest product, fell to 60%, demonstrating that its algorithms produce better results over time. Management raised guidance for the year, and it reiterated that it expects to be profitable on an adjusted EBITDA basis before the end of 2026. Lemonade stock soared on the news, and it's up 31% in one day as of this writing. It's likely to stabilize over the next few days, but it looks like it's finally becoming clear to the market that Lemonade is the future of insurance, and at the current price, it still looks like a bargain. Do the experts think Lemonade is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Lemonade make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,039% vs. just 181% for the S&P — that is beating the market by 858.19%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Jennifer Saibil has positions in Lemonade. The Motley Fool has positions in and recommends Lemonade. The Motley Fool has a disclosure policy. Why Lemonade Stock Dropped 14% in July, and Why It's Already Rebounding was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61. The company reported sales of $2.50 billion, up 4% year over year, beating the consensus of $2.41 billion. On an organic operational basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024. Revenue in the U.S. segment was $1.4 billion, up 4% and 7% on an organic operational of the company's companion animal products increased 9%, driven primarily by Simparica Trio, the company's flea, tick, and heartworm combination product, as well as its key dermatology portfolio, including Apoquel, Apoquel Chewable, and Cytopoint. Broad-based growth across the remainder of the companion animal portfolio, including vaccines and diagnostics, was partially offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs, and Solensia for cats. Sales of livestock products declined 21% in the quarter, largely due to the divestiture of the medicated feed additive product portfolio and related assets. On an organic operational basis, sales of livestock products decreased 2% in the quarter due to the timing of supply of ceftiofur products and competition for Draxxin, partially offset by growth across the livestock portfolio, primarily in vaccines. Guidance Zoetis raised its fiscal 2025 revenues guidance from $9.425 billion–$9.575 billion to $9.45 billion-$9.6 billion, compared to the consensus of $9.49 billion. View more earnings on ZTS The animal health company also raised the 2025 adjusted earnings per share from $6.20-$6.30 to $6.30-$6.40, compared to the consensus of $6.23. The company expects adjusted net income of $2.825 billion-$2.875 billion compared to the prior guidance of $2.775 billion-$2.825 billion. The company says the guidance reflects foreign exchange rates and the impact of enacted tariffs. With an eye on future growth, William Blair noted that sentiment around Librela, a key product in Zoetis's portfolio, remains subdued. However, they argue that the product's decline in the U.S. market may not significantly impact overall performance, particularly given the robust performance in the U.S. companion animal segment, which saw strong growth. The momentum in this area appears sufficient to offset the challenges posed by Librela's underperformance. Brandon Vazquez, an analyst at William Blair, commented, 'Investors have been questioning how Zoetis can sustain growth within its long-range plan amid rising competition and struggles with Librela. We think second-quarter results and raised full-year guidance should give incremental confidence that this is not the case.' Zoetis saw its shares initially rise following the release of its stronger-than-expected second-quarter results, alongside an upward revision of its fiscal 2025 EPS and revenue guidance. However, despite the positive report and raised outlook, Zoetis stock has since retraced its earlier gains. Price Action: ZTS stock is trading lower by 2.62% to $147.84 at last check Tuesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for ZTS Date Firm Action From To Mar 2022 Citigroup Maintains Neutral Dec 2021 Citigroup Maintains Neutral Nov 2021 Morgan Stanley Initiates Coverage On Overweight View More Analyst Ratings for ZTS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ZOETIS (ZTS): Free Stock Analysis Report This article Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
8 minutes ago
- Forbes
Should You Buy Kenvue Stock At $22?
Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental weaknesses that render the stock unattractive for new investors at this time. Kenvue became an independent entity in May 2023 after its spinoff from Johnson & Johnson's consumer health division. As a global consumer health company, Kenvue has shifted from being part of a healthcare conglomerate to functioning as a standalone public company within a competitive consumer products market. That being said, if you are looking for upside with less volatility compared to individual stocks, the Trefis High Quality portfolio serves as an alternative — having outperformed the S&P 500 and delivered returns that exceed 91% since its establishment. Also, see – UNH Stock To $160? Valuation Analysis: Premium Pricing Kenvue is trading at a considerable premium to the overall market across key valuation metrics: While the P/S ratio seems reasonable, the high P/E and P/FCF multiples indicate that investors are paying a significant premium for every dollar of earnings and free cash flow generated. Check out – Kenvue Valuation Ratios – for more information. Growth Performance: Declining Trajectory Kenvue's revenue growth profile shows concerning patterns that do not justify its premium valuation: The ongoing revenue challenges suggest systemic issues in Kenvue's core markets and competitive stance. Profitability Assessment: Mediocre Margins Kenvue's profitability metrics hover around median levels but do not meet market standards: Financial Stability: Adequate but Unremarkable Kenvue sustains satisfactory financial health without notable strengths: Investment Conclusion Kenvue's stock valuation lacks support from its underlying fundamentals. Inconsistent growth and average profitability do not justify the high price relative to the overall market. Although Kenvue enjoys financial stability and operates in the defensive consumer health sector, these favorable attributes are already priced into the current stock value. The combination of high valuation and weak operational fundamentals makes KVUE an unattractive investment opportunity at present levels. Investors looking for exposure to consumer health may be better off waiting for a more favorable entry point or exploring alternatives with stronger growth prospects and more reasonable valuations. See, there is always a notable risk associated with investing in a single or a small number of stocks. Consider TrefisHigh Quality (HQ) Portfolio which, consisting of 30 stocks, has a history of successfully outperforming the S&P 500 over the past 4-year period. Why is that? Collectively, HQ Portfolio stocks have provided superior returns with less risk compared to the benchmark index; a more stable investment experience, as demonstrated in HQ Portfolio performance metrics.
